TW202525865A - 融合蛋白在治療年齡相關性黃斑變性中的應用 - Google Patents

融合蛋白在治療年齡相關性黃斑變性中的應用 Download PDF

Info

Publication number
TW202525865A
TW202525865A TW113142581A TW113142581A TW202525865A TW 202525865 A TW202525865 A TW 202525865A TW 113142581 A TW113142581 A TW 113142581A TW 113142581 A TW113142581 A TW 113142581A TW 202525865 A TW202525865 A TW 202525865A
Authority
TW
Taiwan
Prior art keywords
eye
once
weeks
ibi302
fusion protein
Prior art date
Application number
TW113142581A
Other languages
English (en)
Chinese (zh)
Inventor
盧淑傑
錢鐳
Original Assignee
大陸商信達生物製藥（蘇州）有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 大陸商信達生物製藥（蘇州）有限公司 filed Critical 大陸商信達生物製藥（蘇州）有限公司
Publication of TW202525865A publication Critical patent/TW202525865A/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
TW113142581A 2019-12-24 2020-12-23 融合蛋白在治療年齡相關性黃斑變性中的應用 TW202525865A (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
CN201911346311 2019-12-24
CN201911346311.2 2019-12-24
CN202011441025 2020-12-11
CN202011441025.7 2020-12-11

Publications (1)

Publication Number Publication Date
TW202525865A true TW202525865A (zh) 2025-07-01

Family

ID=76575187

Family Applications (2)

Application Number Title Priority Date Filing Date
TW113142581A TW202525865A (zh) 2019-12-24 2020-12-23 融合蛋白在治療年齡相關性黃斑變性中的應用
TW109145708A TWI879855B (zh) 2019-12-24 2020-12-23 融合蛋白在治療年齡相關性黃斑變性中的應用

Family Applications After (1)

Application Number Title Priority Date Filing Date
TW109145708A TWI879855B (zh) 2019-12-24 2020-12-23 融合蛋白在治療年齡相關性黃斑變性中的應用

Country Status (8)

Country Link
US (1) US20230056821A1 (enExample)
EP (1) EP4082559A4 (enExample)
JP (2) JP2023509880A (enExample)
CN (2) CN118750581A (enExample)
AU (2) AU2020414152B2 (enExample)
CA (1) CA3165887A1 (enExample)
TW (2) TW202525865A (enExample)
WO (1) WO2021129658A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20240329A1 (es) 2019-06-05 2024-02-27 Regeneron Pharma Dispositivos y metodos para administracion de dosis de precision
FI4185318T3 (fi) 2021-05-17 2025-10-13 Regeneron Pharma Pitkäaikaisia, suuren annoksen VEGF-antagonistihoitoja angiogeenisten silmäsairauksien hoitoon
US12649031B2 (en) 2021-09-08 2026-06-09 Regeneron Pharmaceuticals, Inc. Methods for delivering agents with pre-filled syringes to minimize intraocular inflammation
USD1120314S1 (en) 2022-11-30 2026-03-24 Regeneron Pharmaceuticals, Inc. Dose delivery device
CN117467025B (zh) * 2023-12-28 2024-04-16 上海鼎新基因科技有限公司 一种抗vegf和补体双功能融合蛋白及其应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112014013205A2 (pt) * 2011-12-01 2020-10-27 Protevobio, Inc. proteína de fusão, seu uso e seu método de produção, composição farmacêutica, ácido nucleico, e kit
CN104940926B (zh) * 2014-09-25 2017-09-22 信达生物制药(苏州)有限公司 重组融合蛋白制剂
CN105435222B (zh) * 2014-09-25 2018-05-29 信达生物制药(苏州)有限公司 重组融合蛋白制剂

Also Published As

Publication number Publication date
WO2021129658A1 (zh) 2021-07-01
TWI879855B (zh) 2025-04-11
AU2020414152B2 (en) 2025-02-13
EP4082559A4 (en) 2024-01-03
EP4082559A1 (en) 2022-11-02
CN114867489A (zh) 2022-08-05
AU2025203373A1 (en) 2025-05-29
JP2024167222A (ja) 2024-12-03
TW202128746A (zh) 2021-08-01
AU2020414152A1 (en) 2022-08-04
JP2023509880A (ja) 2023-03-10
CA3165887A1 (en) 2021-07-01
CN118750581A (zh) 2024-10-11
US20230056821A1 (en) 2023-02-23

Similar Documents

Publication Publication Date Title
TWI879855B (zh) 融合蛋白在治療年齡相關性黃斑變性中的應用
US20250268983A1 (en) Use of a VEGF Antagonist to Treat Angiogenic Eye Disorders
AU2022275786B2 (en) Extended, high dose VEGF antagonist regimens for treatment of angiogenic eye disorders
US11052130B2 (en) Method for treating eye diseases with a fusion protein of a tissue-penetrating peptide and anti-vascular endothelial growth factor
US11478465B2 (en) Compounds for treatment of eye diseases associated with excessive vascularisation
MXPA04004363A (es) Procedimientos para tratar enfermedades neovasculares oculares.
WO2025036488A9 (en) Methods of treating age-related macular degeneration and diabetic macular edema
EP4640702A1 (en) Use of alpha-2,6-sialylated immunoglobulin in preventing or treating dry eye syndrome or inflammatory eye diseases
Hakan et al. Evaluation Of The Effectiveness Of Intravitreal Anti-VEGF Injection With Intravitreal Dexamethasone Implant In Patients With Treatment-Resistant Diabetic Macular Edema
EA051980B1 (ru) Расширенные схемы применения высоких доз антагониста vegf для лечения ангиогенных нарушений со стороны глаза
Şimdivar et al. Comparison of Ranibizumab Efficacy in Treatment-Naive and Previously Treated Patients with Diabetic Macular Edema and Evaluation of Prognostic Parameters
HK40125761A (en) Use of a vegf antagonist to treat angiogenic eye disorders
HK40094966A (en) Use of a vegf antagonist to treat diabetic retinopathy
EA046420B1 (ru) Применение антагониста vegf для лечения ангиогенных глазных заболеваний
Fernandez-Lloris Association for Research in Vision and Ophthalmology (ARVO)-2015 Annual Meeting. Denver, Colorado, USA-May 3-7, 2015
OPTHALMOLOGY A MULTIVARIATE ANALYSIS OF INTRA VITREAL INJECTION OF ANTI VEGF BEVACIZUMAB IN THE TREATMENT OF RETINAL AND CHOROIDAL NEOVASCULARISATION